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Need for Speed
In a systematic review of 
the literature, Nast and 
colleagues examined the 
time until onset of action 
(TOA) of systemic agents 
used to treat moderate to 
severe psoriasis because 
this factor has been largely 
ignored in treatment 
recommendations despite 
the importance to patients 
of a fast response. A review 
of 49 studies revealed 
that infliximab had the 
shortest TOA, followed by 
ustekinumab, adalimumab, 
cyclosporin A, etanercept, 
and alefacept. TOA should 
be included in clinical trial 
reporting in the future to 
guide clinical treatment 
decisions. See page 1963 
T-Antigen Addiction
Merkel cell carcinoma (MCC) 
is an aggressive cancer 
characterized by expression 
of small and large T antigens 
(sT and LT) of the causative 
Merkel cell polyomavirus 
(MCV); however, the extent 
to which these cancer 
cells are addicted to sT 
and LT remains unknown. 
Angermeyer and colleagues 
confirmed the reported 
transforming effects of sT 
and demonstrated that 
MCC cells do not require 
sT expression, whereas LT, 
which is not sufficient for 
transformation, is required 
for the growth and survival 
of MCV+MCC cells. Thus, LT 
is the more useful potential 
target for development of 
therapeutic interventions for 
this deadly cancer.  
See page 2059
Mosaic RASopathies
Phacomatosis pigmentokeratotica (PPK) is characterized 
by the coexistence of a sebaceous nevus and a speckled 
lentiginous nevus. The occurrence of two nevus types in 
one patient has been ascribed to nonallelic twin spotting 
(didymosis); however, Groesser and colleagues identified a 
dominant activating HRAS mutation in both the sebaceous 
and the melanocytic nevi in several PPK patients. These 
investigators propose that the mutation occurs in a multi-
potent progenitor cell that gives rise to both the cutaneous 
and the extracutaneous anomalies. The findings incorporate 
PPK into the group of mosaic RASopathies, a term suggested 
for congenital disorders caused by mosaic mutations of the 
same pathway. See page 1998 
Suitable Carriers
Vaccines are typically administered via 
injection into sites, such as muscles, that 
are not particularly immunologically 
active. Baleeiro and colleagues exam-
ined the utility of layer by layer–coated 
SiO2 particles for delivery of vaccine 
antigens into the cross-presentation 
pathway of human skin dendritic cells 
(DCs), which are important targets and 
mediators of prophylactic and thera-
peutic vaccination. When antigen and 
Toll-like-receptor adjuvant were admin-
istered together, the DCs fully matured and triggered T-cell activation. Furthermore, 
these particles penetrated into hair follicles and were retained for days. Efficient deliv-
ery of antigen to the DCs indicates that these microparticles are suitable carriers for 
topical vaccines to induce cell-mediated immunity. See page 1933 
The Burden of AK
The prevalence and associated risk factors 
for actinic keratoses (AKs) were investigated 
in 2,061 Dutch participants as part of the 
Rotterdam Study. AKs occurred in 38% of 
this older population (49% of men and 28% 
of women), and 8% of participants had 10 
or more AKs. The prevalence was highest in 
people 50 years old or older. Severe bald-
ness was the strongest risk factor for AK in 
men. These data underscore the burden of 
AKs to the health-care system and fuel the 
controversy about whether to treat these 
lesions given that only some will progress 
to squamous cell carcinoma. See page 1971
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